These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 2251191)

  • 1. Use of amphotericin B in immunosuppressed patients with cancer. Part One: Pharmacology and toxicities.
    Rutledge DN; Holtzclaw BJ
    Oncol Nurs Forum; 1990; 17(5):731-6. PubMed ID: 2251191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of amphotericin B in immunosuppressed patients with cancer. Part Two: Pharmacodynamics and nursing implications.
    Holtzclaw BJ; Rutledge DN
    Oncol Nurs Forum; 1990; 17(5):737-42. PubMed ID: 2251192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liposomal amphotericin B for the treatment of severe fungal infection.
    Michaud D
    Dynamics; 2001; 12(1):17-21. PubMed ID: 11982230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The novel lipid delivery system of amphotericin B: drug profile and relevance to clinical practice.
    Rust DM; Jameson G
    Oncol Nurs Forum; 1998; 25(1):35-48. PubMed ID: 9460772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amphotericin B deoxycholate (d-AMB) use in cases with febrile neutropenia and fungal infections: lower toxicity with suitable premedication.
    Oto OA; Paydas S; Disel U; Yavuz S; Seydaoglu G
    Mycoses; 2007 Mar; 50(2):135-9. PubMed ID: 17305778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Liposomal amphotericin B in the treatment of severe fungal infections. Results of a clinical cohort trial].
    Rieger CT; Dittmer M; Ostermann H
    Dtsch Med Wochenschr; 2007 Oct; 132(40):2062-6. PubMed ID: 17899499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of systemic fungal infections with liposomal amphotericin B.
    Lopez-Berestein G; Bodey GP; Fainstein V; Keating M; Frankel LS; Zeluff B; Gentry L; Mehta K
    Arch Intern Med; 1989 Nov; 149(11):2533-6. PubMed ID: 2818111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Must we be really concerned about amphotericin B toxicity in oncology patients?].
    Mayer J; Doubek M
    Cas Lek Cesk; 1998 Oct; 137(20):632-6. PubMed ID: 9863267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical roundtable monograph: safety and efficacy of lipid-based amphotericin B.
    Bellmann R; Cleary JD; Sterba J
    Clin Adv Hematol Oncol; 2009 Apr; 7(4):1-8. PubMed ID: 19537331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Ambulatory therapy with amphotericin B].
    Berger C; Gratwohl A; Tichelli A; Osterwalder B; Levak A; Nussbaumer B; Peña E; Honkanen H; Speck B
    Schweiz Med Wochenschr; 1988 Apr; 118(16):592-6. PubMed ID: 3381073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of amphotericin B lipid complex injection (ABLC) in bone marrow transplant recipients with life-threatening systemic mycoses.
    Wingard JR
    Bone Marrow Transplant; 1997 Feb; 19(4):343-7. PubMed ID: 9051244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meta-analysis of nebulized amphotericin B to prevent or treat pulmonary aspergillosis in immunosuppressed animals.
    Ho KM; Duff O; Chambers D; Murray R
    Transpl Infect Dis; 2008 Jun; 10(3):168-76. PubMed ID: 18194368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of nefopam for the prevention and treatment of amphotericin B-induced shivering.
    Rosa G; Dell'Utri D; Conti G; Pelaia P; Cogliati A; Orsi P; Gasparetto A
    Arch Intern Med; 1997 Jul; 157(14):1589-92. PubMed ID: 9236561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amphotericin B: 30 years of clinical experience.
    Gallis HA; Drew RH; Pickard WW
    Rev Infect Dis; 1990; 12(2):308-29. PubMed ID: 2184499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retrospective review of amphotericin B use in a tertiary-care medical center.
    Gross MH; Pickard WW; Perfect JR
    Am J Hosp Pharm; 1987 Jun; 44(6):1353-7. PubMed ID: 3618612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized trial of fluconazole versus low-dose amphotericin B in prophylaxis against fungal infections in patients undergoing hematopoietic stem cell transplantation.
    Koh LP; Kurup A; Goh YT; Fook-Chong SM; Tan PH
    Am J Hematol; 2002 Dec; 71(4):260-7. PubMed ID: 12447954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The reformulation of amphotericin B for oral administration to treat systemic fungal infections and visceral leishmaniasis.
    Thornton SJ; Wasan KM
    Expert Opin Drug Deliv; 2009 Mar; 6(3):271-84. PubMed ID: 19327044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of aerosolized liposomal versus deoxycholate amphotericin B formulations for prevention of invasive fungal infections following lung transplantation: a retrospective study.
    Lowry CM; Marty FM; Vargas SO; Lee JT; Fiumara K; Deykin A; Baden LR
    Transpl Infect Dis; 2007 Jun; 9(2):121-5. PubMed ID: 17461997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome.
    Mattiuzzi GN; Estey E; Raad I; Giles F; Cortes J; Shen Y; Kontoyiannis D; Koller C; Munsell M; Beran M; Kantarjian H
    Cancer; 2003 Jan; 97(2):450-6. PubMed ID: 12518369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implementation of clinical practice policy on the continuous intravenous administration of amphotericin B deoxycholate.
    Maharom P; Thamlikitkul V
    J Med Assoc Thai; 2006 Nov; 89 Suppl 5():S118-24. PubMed ID: 17718252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.